Molecular Pharmaceutics

OCT 24, 2026 · JOURNAL ARTICLE

Development of a 18F-Radiolabeled CD38 Probe for Targeted PET Imaging of NSCLC Xenografts with Different EGFR-Mutant Status

Molecular Pharmaceutics

Abstract Non-invasive identification of epidermal growth factor receptor (EGFR) mutation status remains a critical unmet clinical need for personalized therapy of non-small-cell lu

OCT 24, 2026 · JOURNAL ARTICLE

Dual-Targeting Liposomes Based on Ginsenoside Rg3 for Intercepting the Metastatic Cascade in Breast Cancer

Molecular Pharmaceutics

Abstract Metastatic progression remains the primary cause of mortality in triple-negative breast cancer. However, unmodified cholesterol-based liposomes displayed inherent limitati

OCT 14, 2026 · JOURNAL ARTICLE

Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics

Molecular Pharmaceutics

Abstract Claudin 18.2 (CLDN18.2) is a tight junction protein aberrantly expressed in gastric and pancreatic cancer. In this study, we developed the novel nanobody 18.2−50H and VHH-

OCT 8, 2026 · JOURNAL ARTICLE

mRNA Delivery with Lipopolymers to Rejuvenate TRAIL Therapy for Lung Cancer Treatment

Molecular Pharmaceutics

Abstract Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) has long been identified as a promising therapeutic due to its ability to induce apoptosis selectively in c

OCT 7, 2026 · JOURNAL ARTICLE

BBR-RHE Co-Loaded Nanoemulsion Potentiates Anti-PD-L1 Efficacy via Lipid Metabolic Reprogramming in Triple-Negative Breast Cancer

Molecular Pharmaceutics

Abstract Triple-negative breast cancer (TNBC) therapy is limited by the poor efficacy of anti-programmed death-ligand 1 (aPD-L1) monotherapy, with dysregulated lipid metabolism in

OCT 7, 2026 · JOURNAL ARTICLE

Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer

Molecular Pharmaceutics

Abstract The application of antibody-drug conjugate (ADC) therapies in advanced bladder cancers may be improved through non-invasive molecular imaging and therapy with targeted rad

SEP 28, 2026 · JOURNAL ARTICLE

Characterization of a 64Cu-Labeled Heterobivalent Bicyclic Peptide (Nectin-4/Albumin) for Targeting of Tumor-Associated Nectin-4

Molecular Pharmaceutics

Abstract The cell adhesion protein Nectin-4 has been proven as an effective target for therapeutic approaches in bladder cancer. In addition, the interest as a target protein for t

SEP 25, 2026 · JOURNAL ARTICLE

Overcoming Solubility and Aggregation: Water-Soluble Porphyrins in Modern Phototherapy

Molecular Pharmaceutics

Abstract Photodynamic therapy (PDT) is a minimally invasive cancer treatment that works through the combined use of photosensitizers (PS), light, and molecular oxygen to generate r